Phase I/II study of T-DM1 alone versus T-DM1 and metronomic temozolomide in secondary prevention of HER2-Positive breast cancer brain metastases following stereotactic radiosurgery

被引：0
|
作者：
Zimmer, Alexandra S.
Gril, Brunilde
Steinberg, Seth
Smart, DeeDee
Gilbert, Mark
Armstrong, Teri
Xiao, Lin
Houston, Nicole
Biassou, Nadia
Brastianos, Priscilla
Carter, Scott
Lyden, David C.
Lipkowitz, Stanley
Steeg, Patricia
机构：
[1] NCI, Womens Malignancies Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, NIH, Bethesda, MD 20892 USA
[3] NCI, Radiat Oncol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA
[4] NCI, Neurooncol Branch, NIH, Bethesda, MD 20892 USA
[5] NIH, Neuroradiol, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA
[6] Massachusetts Gen Hosp, Harvard Canc Ctr, Boston, MA 02114 USA
[7] Dana Farber Canc Inst, Boston, MA 02115 USA
[8] Weill Cornell Med, New York, NY USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-06-01
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
    Thibault, C.
    ONCOLOGIE, 2013, 15 (02) : 126 - 127
  • [22] Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive breast cancer
    Sliwkowski, Mark X.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [23] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
    Jacot, William
    Pons, Elvire
    Frenel, Jean-Sebastien
    Guiu, Severine
    Levy, Christelle
    Heudel, Pierre Etienne
    Bachelot, Thomas
    D'Hondt, Veronique
    Darlix, Amelie
    Firmin, Nelly
    Romieu, Gilles
    Thezenas, Simon
    Dalenc, Florence
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (02) : 307 - 318
  • [24] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
    William Jacot
    Elvire Pons
    Jean-Sébastien Frenel
    Séverine Guiu
    Christelle Levy
    Pierre Etienne Heudel
    Thomas Bachelot
    Véronique D’Hondt
    Amélie Darlix
    Nelly Firmin
    Gilles Romieu
    Simon Thezenas
    Florence Dalenc
    Breast Cancer Research and Treatment, 2016, 157 : 307 - 318
  • [25] Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer
    Jain, S.
    Nye, L.
    Santa-Maria, C.
    Bontemps, L.
    Williams, A.
    Garrett, H.
    Dammrich, E.
    Giles, F.
    Gradishar, W.
    CANCER RESEARCH, 2016, 76
  • [26] Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer
    Ma, Bo
    Ma, Qianqian
    Wang, Hongqiang
    Zhang, Guolei
    Zhang, Huiying
    Wang, Xiaohong
    ONCOTARGETS AND THERAPY, 2016, 9 : 959 - 976
  • [27] Pertuzumab and T-DM1: New perspectives in the treatment of HER2-positive breast cancer
    Guiu, S.
    Fumoleau, P.
    ONCOLOGIE, 2015, 17 (5-6) : 263 - 270
  • [28] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
    Hunter, Francis W.
    Barker, Hilary R.
    Lipert, Barbara
    Rothe, Francoise
    Gebhart, Geraldine
    Piccart-Gebhart, Martine J.
    Sotiriou, Christos
    Jamieson, Stephen M. F.
    BRITISH JOURNAL OF CANCER, 2020, 122 (05) : 603 - 612
  • [29] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
    Francis W. Hunter
    Hilary R. Barker
    Barbara Lipert
    Françoise Rothé
    Géraldine Gebhart
    Martine J. Piccart-Gebhart
    Christos Sotiriou
    Stephen M. F. Jamieson
    British Journal of Cancer, 2020, 122 : 603 - 612
  • [30] Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
    Matthew N. Mills
    Chelsea Walker
    Chetna Thawani
    Afrin Naz
    Nicholas B. Figura
    Sergiy Kushchayev
    Arnold Etame
    Hsiang-Hsuan Michael Yu
    Timothy J. Robinson
    James Liu
    Michael A. Vogelbaum
    Peter A. Forsyth
    Brian J. Czerniecki
    Hatem H. Soliman
    Hyo S. Han
    Kamran A. Ahmed
    BMC Cancer, 21
12345